ArticleJournal of neuro-oncology2000
Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
Article in Journal of neuro-oncology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 59 citations in OpenAlex.
- The prognostic significance of p16 expression pattern in diffuse gliomas.Journal of pathology and translational medicine · 2021Article
- A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2016Observational
- Biomarkers in precision therapy in colorectal cancer.Gastroenterology report · 2013Article
- Biologic tumor behavior in pilocytic astrocytomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Pediatric glioblastomas: a histopathological and molecular genetic study.Neuro-oncology · 2009Article
- Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer.World journal of gastroenterology · 2007Article
- The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas.Neoplasia (New York, N.Y.) · 2006Article
- Role of MIB1 in predicting survival in patients with glioblastomas.Journal of neuro-oncology · 2006Article
- Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer.World journal of gastroenterology · 2005Article
- Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.Journal of neuro-oncology · 2004Article
- Immunohistochemical markers for prognosis of anaplastic astrocytomas.Journal of neuro-oncology · 2002Article
- Immunohistochemical markers for prognosis of oligodendroglial neoplasms.Journal of neuro-oncology · 2002Article
- Immunohistochemical markers for prognosis of ependymal neoplasms.Journal of neuro-oncology · 2002Article
- The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line.World journal of gastroenterology · 2002Article
- Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.Journal of neuro-oncology · 2002Article
- Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology.Brain pathology (Zurich, Switzerland) · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cumulative inactivation of tumor suppressor genes and/or amplification of oncogenes lead to progressively more malignant astrocytic tumors. We have analyzed the significance of tumor suppressor genes p53, p21, p16 and retinoblastoma protein (pRb) and proliferative activity for survival in 77 high grade astrocytic tumors. After operation, the patients--25 anaplastic astrocytomas (AA) and 52 glioblastomas (GBs)--were treated with similar radiotherapy. The expression of the suppressor genes and the proliferative activity were analyzed immunohistochemically. p53 immunopositivity was found in 44% of AAs and 46% of GBs. Tumors with aberrant p53 expression had lower proliferation indices than p53 immunonegative tumors. Neither p53 expression nor p21 immunonegativity (52% of AAs and 48% of GBs) correlated with survival. p16 immunostaining was negative in 16% of AAs and in 44% of GBs, and it correlated inversely with survival in both uni- and multivariate analyses. pRb immunostaining was negative only in 8% of both AAs and GBs and the absence of p16 and pRb were mutually exclusive. Ki-67 labelling index (LI) was significantly higher in GBs (26.8%) than in AAs (20.3%), and in multivariate analysis it was an independent prognostic factor for survival. In 48% of AAs Ki-67 LI exceeded 20% and this subset of AAs had similar prognosis as GB. In high grade astrocytic tumors p16 immunonegativity was an independent indicator of poor prognosis in addition to the previously established patient's age, histopathology and Ki-67 LI. Furthermore, there was a subset of AAs with a high proliferation rate (> 20%) in which the histopathological hallmarks of GB were lacking, but which had similarly dismal prognosis as GB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.